Prospects of HIV Env modification as an approach to HIV vaccine design

被引:41
作者
Hu, Shiu-Lok [2 ,3 ]
Stamatatos, Leonidas [1 ,4 ]
机构
[1] Seattle Biomed Res Inst, Seattle, WA 98109 USA
[2] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
[3] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
关键词
HIV Env; Env modifications; neutralizing antibodies; HIV vaccines;
D O I
10.2174/157016207782418542
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
So far, all efforts to engineer immunogens that would elicit broadly reactive anti-HIV neutralizing antibody responses have not been Successful. In the past few years, however, key information on the structure of the epitopes recognized by several broadly reactive anti-HIV neutralizing antibodies (NAbs), the structures of these NAbs themselves and the molecular interaction between these NAbs and their epitopes has emerged, that promises to guide the design of better immunogens. In order to enhance the immunogenicity of conserved neutralization epitopes on Env, certain modifications such as variable loop-deletion, elimination of glycosylation sites, or epitope-repositioning, are being investigated. So far, however, all available data from immunization studies indicate that the effect such structural modifications have on Env immunogenicity is unpredictable. This implies that despite the significant progress made in elucidating the interaction of NAbs with their targets at the molecular level, a significant iterative effort is required to identify immunogens that would elicit the much anticipated broad anti-HIV neutralizing antibody responses.
引用
收藏
页码:507 / 513
页数:7
相关论文
共 83 条
[1]   AN N-GLYCAN WITHIN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 V3 LOOP AFFECTS VIRUS NEUTRALIZATION [J].
BACK, NKT ;
SMIT, L ;
DEJONG, JJ ;
KEULEN, W ;
SCHUTTEN, M ;
GOUDSMIT, J ;
TERSMETTE, M .
VIROLOGY, 1994, 199 (02) :431-438
[2]   Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 [J].
Beddows, S ;
Schülke, N ;
Kirschner, M ;
Barnes, K ;
Franti, M ;
Michael, E ;
Ketas, T ;
Sanders, RW ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2005, 79 (14) :8812-8827
[3]   A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120 [J].
Beddows, Simon ;
Franti, Michael ;
Dey, Antu K. ;
Kirschner, Marc ;
Iyer, Sal Prasad N. ;
Fisch, Danielle C. ;
Ketas, Thomas ;
Yuste, Eloisa ;
Desrosiers, Ronald C. ;
Klasse, Per Johan ;
Maddon, Paul J. ;
Olson, William C. ;
Moore, John P. .
VIROLOGY, 2007, 360 (02) :329-340
[4]   INFLUENCE OF CARBOHYDRATE MOIETIES ON THE IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GP160 [J].
BENJOUAD, A ;
GLUCKMAN, JC ;
ROCHAT, H ;
MONTAGNIER, L ;
BAHRAOUI, E .
JOURNAL OF VIROLOGY, 1992, 66 (04) :2473-2483
[5]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN IS MODIFIED BY O-LINKED OLIGOSACCHARIDES [J].
BERNSTEIN, HB ;
TUCKER, SP ;
HUNTER, E ;
SCHUTZBACH, JS ;
COMPANS, RW .
JOURNAL OF VIROLOGY, 1994, 68 (01) :463-468
[6]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[7]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[8]   Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response [J].
Bolmstedt, A ;
Sjolander, S ;
Hansen, JES ;
Akerblom, L ;
Hemming, A ;
Hu, SL ;
Morein, B ;
Olofsson, S .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1996, 12 (03) :213-220
[9]   Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals - Effects of elimination of the V3N306 glycan [J].
Bolmstedt, A ;
Hinkula, J ;
Rowcliffe, E ;
Biller, M ;
Wahren, B ;
Olofsson, S .
VACCINE, 2001, 20 (3-4) :397-405
[10]   Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity [J].
Braibant, Martine ;
Brunet, Sylvie ;
Costagliola, Dominique ;
Rouzioux, Christine ;
Agut, Henri ;
Katinger, Hermann ;
Autran, Brigitte ;
Barin, Francis .
AIDS, 2006, 20 (15) :1923-1930